Please congratulate our incoming leaders, whose terms will officially begin on Dec 1! Co-Presidents Jesse Boehm, PhD Alice Soragni, PhD @alice.soragnilab.com Secretary Keith Ligon, MD, PhD Board Member At-Large Noah Berlow, PhD We offer our deep appreciation to the outgoing Board members.

𝗦𝗙𝗣𝗠 𝗠𝗲𝗺𝗯𝗲𝗿𝘀 – 𝗬𝗼𝘂𝗿 𝗩𝗼𝗶𝗰𝗲 𝗠𝗮𝘁𝘁𝗲𝗿𝘀! Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission. ✅ Vote now: sfpm.membershiptoolkit.com

𝗦𝗙𝗣𝗠 𝗠𝗲𝗺𝗯𝗲𝗿𝘀 – 𝗬𝗼𝘂𝗿 𝗩𝗼𝗶𝗰𝗲 𝗠𝗮𝘁𝘁𝗲𝗿𝘀! Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission. ✅ Vote now: sfpm.membershiptoolkit.com

🚨Excited to announce the seminar by Kushtrim Kryeziu, PhD (Oslo University) on "Functional Precision Oncology for Metastatic Colorectal Cancer". Join us TODAY, at 12 PM EDT, open to everyone! Don't miss it and consider joining the SFPM www.sfpm.io/seminars

What incredible news today. I feel so grateful to have worked closely with Tony over the years and to have witnessed firsthand his vision, energy, and commitment to advancing functional precision medicine. I cannot think of a steadier (and more needed) force at the NCI at this time /n

The Society for Functional Precision Medicine@thesfpm.bsky.social · 12mo ago

We want to congratulate our President, Dr. Tony Letai, on his appointment as Director of the NCI. This announcement marks an historic moment for cancer research. Dr. Letai has been a tireless advocate and visionary leader for functional precision medicine 🧵 www.nih.gov/news-events/...

We want to congratulate our President, Dr. Tony Letai, on his appointment as Director of the NCI. This announcement marks an historic moment for cancer research. Dr. Letai has been a tireless advocate and visionary leader for functional precision medicine 🧵 www.nih.gov/news-events/...

Secretary Kennedy Swears in Dr. Anthony Letai as Director of the National Cancer Institute

Dr. Letai will serve as NCI’s 18th director.

nih.gov

We were honored to host Jens M. Kelm, PhD (PreComb Therapeutics) for our September seminar. Dr. Kelm shared insights on: 🎯 Dynamic Drug Response Profiling at Scale for Functional Precision Oncology If you missed the live session, you can now watch it here: www.youtube.com/watch?v=hIkR...

✨ Excited to announce a talk by Jens M. Kelm, PhD (Founder and CSO PreComb Therapeutics AG) on "Dynamic Drug Response Profiling at Scale for Functional Precision Oncology", Join us next Wednesday, September 10, 2025, at 12 PM EDT. Don't miss it! www.sfpm.io/seminars

Join us this Wednesday 06/11 @ 12:00 PM EST for our monthly SFPM seminar! Dr. Chris Steffi from CompagOs will discuss: "Pioneering Solutions to Understand, Diagnose and Treat Bone Conditions" More info & link to join: www.sfpm.io/seminars

Precision approaches to tackle acquired resistance to cancer, including model-based functional strategies: www.nature.com/articles/s41...

Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer

Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...

nature.com

In panel discussion on regulatory and non-regulatory challenges to the wide adoption of precision diagnostics. Chair Tony Letai. #AACRprecmed25 🧪🧬🖥️

Now: Peter Horak. #AACRprecmed25 🧪🧬🖥️

Now: Keith Ligon. #AACRprecmed25 🧪🧬🖥️

Two of our Board members, Dr. Letai and Dr. Ligon, are part of this #AACRPM25 panel focused on regulatory and non-regulatory challenges to the wide adoption of precision diagnostics

Join us *today* Wednesday 03/12 @ 12:00 PM EST for our monthly SFPM seminar! Dr. Perova from EMBL-EBI will discuss: "Leveraging CancerModels.Org: enhancing precision oncology through collaborative cancer model resources" More info: www.sfpm.io/seminars

Now: Keith Flaherty: Targets and therapeutics in need of functional insights to guide drug development in solid tumors #AACRprecmed25 🧪🧬🖥️

Continued 2: KF: Genetic evidence points to multiple resistance pathways #AACRprecmed25 🧪🧬🖥️ https://aacrjournals.org/clincancerres/article/24/24/6195/15360/Landscape-of-EGFR-Dependent-and-Independent

Now: Jeffrey Tyner: Functional omics for novel therapeutic combinations in myeloid malignancies #AACRprecmed25 🧪🧬🖥️

Continued 2: JT: Experimental approach: primary cells -> overnight exposure -> CITE-seq: dynamic changes and cell persistence under therapeutic selective pressure. With @wondermixtape.bsky.social #AACRprecmed25 🧪🧬🖥️

Now: Coleman Lindsley: Dyanmic assessment in leukemia. What is minimal residual disease and does it matter? #AACRprecmed25 🧪🧬🖥️

Now: Sascha Dietrich: Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies #AACRprecmed25 🧪🧬🖥️

On my way to @theaacr.bsky.social special conference in cancer research: functional and genomic precision medicine in cancer. Who else will be there? @alice.soragnilab.com #AACRprecmed25 www.aacr.org/meeting/aacr...

AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals

Overview for AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals

aacr.org

This first AACR meeting on functional and genomic precision medicine has officially started! Dr. Mardis gave the introductory remarks followed by our first plenary speaker, Dr. Flaherty, who will focus on the collision of genomic and functional precision medicine #AACRPM25

Do not miss this great talk tomorrow at 5pm CET (12pm EDT): Zinaida Perova (EMBL) "Leveraging CancerModels.Org: Enhancing Precision Oncology Through Collaborative Cancer Model Resources". @thesfpm.bsky.social www.sfpm.io/seminars

Join us *today* Wednesday 02/12 @ 12:00 PM EST for our monthly SFPM seminar! Dr. Andrew Satterlee from UNC will discuss overcoming systemic barriers to functional precision medicine using a versatile ex vivo model of patient brain tumors. More info: www.sfpm.io/seminars

An exciting multicenter phase 2 functional precision medicine clinical trial showing how a rapid ex vivo venetoclax sensitivity assay was the strongest predictor for a favorable treatment response and survival in relapsed/refractory secondary AML ashpublications.org/blood/articl...

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial

Key PointsBlast-specific ex vivo venetoclax sensitivity correlated strongly with treatment responses and predicted longer survival.VenEx trial showed that

ashpublications.org

Very interesting functional precision medicine study: glioblastoma patient-derived organoids treated with dual-targeting EGFR-IL13Rα2 CAR-Ts mirrored clinical parameters www.cell.com/cell-stem-ce...

Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy

Logun et al. report a unique phase 1 clinical trial design with parallel assessment of patients and rapidly generated patient-derived tumor organoids for CAR-T cell bioactivity in glioblastoma. They showed that cytokine release and the degree of cytolysis in glioblastoma organoids with autologous CAR-T treatment correlated with clinical patient metrics.

cell.com

Join us *tomorrow* Wednesday 12/11 @ 12:00 PM EST for our last monthly SFPM seminar of the year! Drs. Damle and Pillarisetty from @fredhutch.bsky.social will discuss tumor slice cultures as a window into the human TME. Info to join here: www.sfpm.io/seminars

And we are back in business! Functional precision medicine folks are moving to Bluesky, and so are we. Find out more about what the Society for Functional Precision Medicine does and how to join here: sfpm.io

📢Announcing a call for commentaries! Cancer Discovery wants to hear YOUR thoughts that challenge existing paradigms/shed new light on emerging topics in cancer. Selected pieces will be published in April 2024 and showcased during #AACR24! Email cancerdiscovery@aacr.org with proposals by Nov. 1.